Roche leads pre-JPM deal spree; Roger Perl­mut­ter’s new phar­ma force; In­side Sage’s big tri­umph and fail­ure; Late Fri­day IPO fil­ings; All new drugs in 2023; and more

Wel­come to the first is­sue of End­points Week­ly in 2024! The year is start­ing strong, and there will be no short­age of top­ics for my col­leagues to dis­cuss with JP Mor­gan con­fer­ence-go­ers. Say hi if you see them in San Fran­cis­co — and for those stay­ing back, you can al­ways at­tend our two-day event vir­tu­al­ly.

Roche leads pre-JPM deal spree

With a trio of new pacts span­ning an­ti­body-drug con­ju­gates, RNA pro­cess­ing mod­u­la­tion and pre­ci­sion on­col­o­gy, Roche is top­ping the chart of pre­cur­sor deals in the lead-up to the JP Mor­gan con­fab. In up­front alone, it spent $50 mil­lion to pair up with MediLink Ther­a­peu­tics, $30 mil­lion up­front with Remix Ther­a­peu­tics and $66 mil­lion with MO­MA Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER